Viridian Therapeutics, Inc. filings document a clinical-stage biotechnology company with common stock listed on Nasdaq under VRDN. The company’s Form 8-K disclosures report financial results, Regulation FD clinical updates, corporate presentations, and material agreements, including underwriting arrangements for common stock offerings.
Viridian’s regulatory filings also cover its thyroid eye disease programs, including elegrobart trial disclosures and updates related to veligrotug, as well as cash resources, research and development activity, and financing transactions. Proxy materials document annual meeting matters, director elections, executive compensation, equity plans, and related governance procedures.
Viridian Therapeutics reported first quarter 2026 results and key pipeline milestones. The company is preparing for a PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease and has submitted a Marketing Authorization Application in Europe, which was accepted for review.
Subcutaneous elegrobart showed positive topline results in two phase 3 REVEAL trials in active and chronic thyroid eye disease, with a Biologics License Application submission planned in Q1 2027. Viridian ended March 31, 2026 with $762 million in cash, cash equivalents, and short-term investments, generated $141 thousand in total revenues, and recorded a net loss of $104.9 million for the quarter.
Viridian Therapeutics reported first quarter 2026 results and key pipeline milestones. The company is preparing for a PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease and has submitted a Marketing Authorization Application in Europe, which was accepted for review.
Subcutaneous elegrobart showed positive topline results in two phase 3 REVEAL trials in active and chronic thyroid eye disease, with a Biologics License Application submission planned in Q1 2027. Viridian ended March 31, 2026 with $762 million in cash, cash equivalents, and short-term investments, generated $141 thousand in total revenues, and recorded a net loss of $104.9 million for the quarter.
Viridian Therapeutics reported first quarter 2026 results and key pipeline milestones. The company is preparing for a PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease and has submitted a Marketing Authorization Application in Europe, which was accepted for review.
Subcutaneous elegrobart showed positive topline results in two phase 3 REVEAL trials in active and chronic thyroid eye disease, with a Biologics License Application submission planned in Q1 2027. Viridian ended March 31, 2026 with $762 million in cash, cash equivalents, and short-term investments, generated $141 thousand in total revenues, and recorded a net loss of $104.9 million for the quarter.
Viridian Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 2, 2026 at 2:00 p.m. Eastern Time. Holders of 103,071,889 shares of common stock as of April 7, 2026 can participate and vote.
Stockholders will elect two Class II directors, ratify the selection of KPMG LLP as independent auditor for 2026, cast an advisory vote on executive compensation, and give advisory input on how often “say‑on‑pay” votes should occur, with the Board recommending the one‑year option.
Viridian Therapeutics reported positive topline phase 3 data from its REVEAL-1 trial of subcutaneous elegrobart in active thyroid eye disease (TED). The Q4W dosing arm achieved a proptosis responder rate of 54% versus 18% for placebo at week 24, meeting the primary endpoint with high statistical significance. The Q8W arm reached a 63% proptosis responder rate versus 18% placebo, and complete resolution of diplopia occurred in 51% of Q4W patients versus 16% on placebo. Elegrobart was generally well tolerated, with low placebo-adjusted rates of hearing impairment and adverse events consistent with the anti‑IGF‑1R class.
Viridian is also advancing veligrotug for TED, supported by positive phase 3 THRIVE and THRIVE‑2 results, and targets a PDUFA action date of June 30, 2026 for veligrotug and a planned BLA submission for elegrobart in Q1 2027. The company ended Q4 2025 with $875 million in cash and expects cash, potential near-term royalty milestones, and future revenues from veligrotug and elegrobart, if approved, to fund current plans through profitability.
Viridian Therapeutics Inc ownership disclosure: The Vanguard Group filed an amendment reporting 0 shares of Common Stock, representing 0% of the class. The filing explains an internal realignment that caused certain Vanguard subsidiaries to report separately from The Vanguard Group, Inc.
The filing lists The Vanguard Group's address as 100 Vanguard Blvd., Malvern, PA and is signed by Ashley Grim as Head of Global Fund Administration on 03/27/2026. The submission states Vanguard entities pursue the same investment strategies post‑realignment.
Viridian Therapeutics Chief Financial Officer files an amended insider transaction report reflecting tax-related share withholding. On the corrected Form 4/A, Seth Harmon is shown disposing of 2,031 shares of Viridian common stock on March 3, 2026 at $30.19 per share to cover tax obligations. Following this tax-withholding disposition, he beneficially owns 7,850 shares of common stock. The amendment updates both the number of shares and the price used to satisfy taxes, as well as the resulting total holdings, compared with the initial Form 4 filed on March 4, 2026.
Viridian Therapeutics Chief Operating Officer Thomas W. Beetham filed an amended insider report updating a prior Form 4. The amendment corrects the number of shares and price involved in a tax-withholding disposition of 3,048 shares of common stock at $30.19 per share on a transaction coded “F.”
These shares were withheld to cover taxes, rather than sold in an open-market trade. After this correction and all transactions reported in the original Form 4, Beetham is shown as beneficially owning 13,361 shares of Viridian Therapeutics common stock directly.
Viridian Therapeutics Chief Legal Officer updates prior tax-related share filing. Jennifer Tousignant filed an amended Form 4 to correct the number of shares and price previously reported as disposed to cover taxes. The amendment now shows a tax-withholding disposition of 1,675 shares of common stock at $30.19 per share on March 3, 2026, leaving her with 3,494 shares of Viridian Therapeutics common stock held directly.
Viridian Therapeutics President and CEO Stephen F. Mahoney disposed of 7,408 shares of common stock on March 3, 2026 at $30.19 per share to cover taxes. This amended Form 4 corrects the share and price figures previously reported and shows he beneficially owns 33,349 shares afterward.
Viridian Therapeutics’ Chief Legal Officer Jennifer Tousignant reported multiple equity compensation transactions. On March 2, 2026, she received a grant of stock options for 119,300 shares and 23,850 restricted stock units, each RSU representing one share of common stock. The option grant vests in 48 equal monthly installments after the grant date, while the RSUs vest over four years, with 25% vesting on each yearly anniversary of the grant date, subject to continued service.
On March 3, 2026, 5,169 RSUs vested and were converted into 5,169 shares of common stock. In connection with this vesting, 1,724 shares of common stock were disposed of at $29.32 per share to cover tax withholding obligations. After these transactions, she directly held 15,510 RSUs and 3,445 shares of common stock.